KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBITDA: 2010-2015

Historic EBITDA for Biocryst Pharmaceuticals (BCRX) over the last 4 years, with Sep 2015 value amounting to -$14.5 million.

  • Biocryst Pharmaceuticals' EBITDA fell 66.40% to -$14.5 million in Q3 2015 from the same period last year, while for Sep 2015 it was -$36.6 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of -$45.3 million for FY2014, which is 50.42% down from last year.
  • According to the latest figures from Q3 2015, Biocryst Pharmaceuticals' EBITDA is -$14.5 million, which was down 402.77% from $4.8 million recorded in Q2 2015.
  • In the past 5 years, Biocryst Pharmaceuticals' EBITDA ranged from a high of $4.8 million in Q2 2015 and a low of -$15.0 million during Q1 2015.
  • Moreover, its 3-year median value for EBITDA was -$10.1 million (2014), whereas its average is -$9.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 124.41% in 2014, then surged by 132.76% in 2015.
  • Biocryst Pharmaceuticals' EBITDA (Quarterly) stood at -$11.0 million in 2011, then grew by 5.86% to -$12.3 million in 2012, then grew by 0.85% to -$5.4 million in 2013, then plummeted by 117.51% to -$11.8 million in 2014, then slumped by 66.40% to -$14.5 million in 2015.
  • Its last three reported values are -$14.5 million in Q3 2015, $4.8 million for Q2 2015, and -$15.0 million during Q1 2015.